Blog

305Day at MIA: A cafecito celebration for our dedicated team

In celebration of 305Day and Employee Appreciation Week, the Miami-Dade Aviation Department (MDAD) provided free cafecitos…

CUPE 1698: Lockout Threat Puts Fraser Valley Library Services at Risk

ABBOTSFORD, British Columbia–(BUSINESS WIRE)–The Fraser Valley Regional Library (FVRL) has issued 72-hour lockout notice to CUPE…

AM Best Revises Outlooks to Positive for Members of Plymouth Rock Assurance Group

OLDWICK, N.J.–(BUSINESS WIRE)–#insurance—AM Best has revised the outlooks to positive from stable and affirmed the Financial…

Limbach Announces Relocation of Corporate Headquarters to Tampa

Part of the Company’s 125th Anniversary Celebration and Continued Evolution into a Building Systems Solutions Firm…

SubcontractorHub Secures Eight-Figure Growth Investment from Curve Partners to Scale AI-Driven Residential Construction Operating System

PARK CITY, Utah–(BUSINESS WIRE)–#AI—SubcontractorHub, the AI-driven operating system for residential construction, today announced it has secured…

The Cannabist Company Further Extends Forbearance Agreement With Senior Noteholders

CHELMSFORD, Mass.–(BUSINESS WIRE)–The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or…

KIRIN HYOKETSU Expands into U.S. RTD Market with Local Production

Strawberry and Pineapple flavors debut in Florida and Hawaii TOKYO–(BUSINESS WIRE)–New Belgium Brewing, the Kirin Group…

REMINDER: Coreweave, Inc. Investors With Significant Losses Must Act By March 13, 2026

NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds Coreweave, Inc. (“Coreweave” or the “Company”) (NASDAQ:CRWV) investors of the…

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and…

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and…